Background and Challenges

Patients with Neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNFs), benign tumors of the peripheral nerves. The progression of these tumors into malignant peripheral nerve sheath tumors (MPNSTs) remains poorly understood. Clinically, the loss of NF1 is followed by the sequential inactivation of p14ARF and p16INK4a, which are encoded by the CDKN2A gene, and this is thought to be a key step in the transition. However, the precise molecular switches that drive this cellular fate change are not fully elucidated. Specifically, it has been hypothesized that the loss of polycomb repressive complex 2 (PRC2), a histone methyltransferase complex, leads to significant changes in chromatin structure and promotes the transition from glial cells to mesenchymal cells. However, a human cell model to directly test this hypothesis has been lacking. Existing animal models do not fully recapitulate the tumor microenvironment or the unique genetic landscape of human tumors, which has been a major obstacle in identifying new therapeutic targets. Therefore, researchers have embarked on an ambitious project to induce neural crest (NC) cells from human induced pluripotent stem cells (iPSCs) and introduce stepwise mutations using CRISPR-based gene editing to 'recreate' human tumor progression in the laboratory.

Model Construction and Discovery of the Transition Mechanism through Gene Editing

NF1 and CDKN2A double-knockout (2KO) iPSC-derived NC cells exhibit inactivation of p14ARF and p16INK4a, and form plexiform neurofibroma-like benign tumors upon subcutaneous implantation in mice. Further knockout (3KO) of EZH2 or SUZ12, core components of PRC2, leads to a dramatic reprogramming of the cellular transcriptional program, silencing the glial cell transcription factor SOX10 and activating mesenchymal transcription factors such as TWIST1 and SNAI2. This transcriptional switch is accompanied by a global reduction in histone H3K27me3 and chromatin opening, resulting in a mixed phenotype that simultaneously exhibits characteristics of both glial cells and mesenchymal stem cells (MSCs). This strikingly recapitulates the PNF-ANNUBP-MPNST continuum observed in actual patient tissues. Implantation of 3KO NC spheroids into the peripheral nerve results in the formation of invasive tumors resembling early-stage MPNSTs, experimentally demonstrating that PRC2 loss is a key trigger that rapidly increases the malignancy of the tumor. In this process, it was revealed that the MAPK pathway is activated simultaneously, and DNA damage repair enzyme PARP1 is excessively dependent, suggesting that the combination of PARP inhibitors and MEK inhibitors (Selumetinib) could selectively induce apoptosis in 3KO cells, which is a new therapeutic strategy.

Discovery of Personalized Therapeutic Combinations through High-Throughput Screening

Using 3D NC spheroids, the research team performed high-throughput screening of over 200 epigenetic drugs, and found that olaparib, a PARP inhibitor, uniquely induces cell death in PRC2-deficient cells. While olaparib alone inhibited only some cells, when used in combination with selumetinib, it produced a synergistic effect by inhibiting the MAPK signaling pathway and blocking DNA repair, resulting in a potent anti-cancer effect that reduced tumor volume by more than 70%. This combination therapy was also well-tolerated and significantly reduced tumor growth rates in a human MPNST PDX (mouse xenograft) model derived from patient samples, suggesting that it could be linked to ongoing Phase II clinical trials (e.g., NCT05812345). Furthermore, this model can be used as a 'personalized treatment platform' to predict drug responses based on individual patient genetic backgrounds (NF1, CDKN2A, and PRC2 status), which will be an important tool in the future era of precision medicine. As a result, the iPSC-based NC model not only elucidates the mechanisms of tumor progression but also serves as an innovative bridge that can rapidly validate drug combinations that can be applied in clinical practice.

Future Implications or Prospects

The iPSC-derived NC 3KO model presented in this study recreates the complex transition process of human MPNST in the laboratory, allowing for a precise exploration of human-specific gene-phenotype interactions that were not possible with existing animal models. Based on this, future research may identify new targets such as PRC2 restoration strategies or SOX10 reactivation, which could lead to the development of preventive therapies to block malignant transformation. In addition, the successful case of olaparib-selumetinib combination provides evidence that the joint use of PARP inhibitors and MAPK inhibitors can be extended to other gliomas or complex tumors, which will be of great help to pharmaceutical companies in designing multi-target clinical trials. At the same time, performing personalized spheroid screening based on patient-specific genetic profiling will make personalized drug prescriptions a reality, which has the potential to significantly expand the rare tumor treatment market, which is currently worth approximately $1 billion annually. Ultimately, this integrated platform will establish a 'bench-to-bedside' pipeline that connects basic science and clinical application, significantly improving the survival rates of MPNST patients and being widely used in research on other similar malignant tumors of the nervous system.